Table 2. Dynamic change of PD-L1 expression in patients with multiple myeloma.

Programmed death-ligand 1 (PD-L1), Autologous stem cell transplant (ASCT)

The overall post-ASCT survival for two patients with initial positive PD-L1 expression prior to the ASCT but becoming negative post-ASCT is 42 months and 29 months, respectively.

The overall post-ASCT survival for three patients with initial negative PD-L1 expression prior to the ASCT but becoming positive post-ASCT is 12 months, 22 months, and 40 months, respectively.

	PD-L1 Negative Post-ASCT	PD-L1 Positive Post-ASCT
PD-L1 Negative Pre-ASCT	18	3
PD-L1 Positive Pre-ASCT	2	3
No data Pre-ASCT	3	3
Summary	23	9